The Effect of Fascia Therapy and Transcutaneous Fibrolysis on Acute Ankle Sprain

NCT ID: NCT01249573

Last Updated: 2011-06-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study investigates the immediate effect of fascia therapy and transcutaneous fibrolysis in the treatment of an acute ankle sprain. These treatments will be compared to a placebo group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ankle sprain is the most occurring sport related injury. In spite of the high prevalence of this injury and the often residual symptoms, there is a large variety in diagnostic approach and therapeutic protocols. Concerning the treatment of an acute ankle sprain, it remains a challenge to minimize injury consequences on short and long term.

In this study we investigate the immediate effect of two therapeutic techniques: fascia therapy and transcutaneous fibrolysis. They will be compared to a third group, who receives a placebo treatment. Muscle strength, muscle vascularisation, muscle tenderness and joint position sense are measured before and after treatment.

The purpose of this study is to contribute to the knowledge of treating acute ankle sprains.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Ankle Distortion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

fascia therapy

arm where fascia therapy is used as a treatment for an acute ankle distortion

Group Type EXPERIMENTAL

fascia therapy or transcutaneous fibrolysis

Intervention Type OTHER

fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion

transcutaneous fibrolysis

arm where transcutaneous fibrolysis is used as a treatment for an acute ankle distortion

Group Type EXPERIMENTAL

fascia therapy or transcutaneous fibrolysis

Intervention Type OTHER

fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion

placebo

arm where placebo therapy is used as a treatment for an acute ankle distortion

Group Type PLACEBO_COMPARATOR

fascia therapy or transcutaneous fibrolysis

Intervention Type OTHER

fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

fascia therapy or transcutaneous fibrolysis

fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* acute ankle sprain

Exclusion Criteria

* none
Minimum Eligible Age

18 Years

Maximum Eligible Age

35 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Ghent

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

University Ghent

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philip Roosen, Prof, PhD

Role: PRINCIPAL_INVESTIGATOR

University Ghent

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital Ghent

Ghent, , Belgium

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Belgium

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EC/2010/580

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.